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Osteoporosis is a condition of deterioration of bone quality and quantity, making it susceptible to fractures. The current 
therapy, with its associated risks and also approval for only short period  makes the search for better molecules on priority 
imperative for effective treatment. Esculetin, a phytoconstituent, known to inhibit osteoclast differentiation in vitro and 
increase bone density in vivo, could serve to cure osteoporosis. Here, we studied the effect of esculetin on the 
microarchitecture of long bones in the ovariectomized rat model. The cellular cause for in vivo effect was sought by studying 
its effect on the pre-osteoblastic cell line. Osteopenia was induced by bilateral ovariectomy. Esculetin @1.0 or 10 mg/kg was 
administered for three months to osteopenic rats. Micro-CT of tibias and femurs was performed. The effect of esculetin on 
pre-osteoblastic MC3T3-E1 cells was studied. Cell viability in the presence of esculetin was determined by MTT assay. 
Alkaline phosphatase activity was determined using p-nitrophenol as a substrate. Bone nodules were stained with Alizarin 
Red S. Esculetin treated groups showed a significant worsening of microarchitecture parameters in the trabecular and 
cortical regions of the femur and tibia. This deterioration was more evident in the trabecular region than the cortical region. 
Esculetin augmented bone loss in estrogen-deficient rats without affecting the cell viability of MC3T3-E1 cells up to a 
concentration of 10 µg/mL. However, it affected the alkaline phosphatase activity and mineralization effect in 
preosteoblastic cells in addition to its in vivo effect in ovariectomized rats. 
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Osteoporosis is a condition of decreased bone mass, 
which increases the susceptibility to fractures. At 
present, the drugs are used to decrease bone 
resorption and/or increase bone formation. As the 
current therapy is associated with risks and approved 
for a short period only, the need for newer better 
molecules for the treatment of osteoporosis is 
imperative. An ideal anti-osteoporotic agent is not yet 
discovered, therefore as of now, it is managed by 
changes in lifestyle along with medicines
1
. Coumarin 
derivative, Osthole, protects against bone loss in 
ovariectomized rats
2,3
. Osthole increases osteoblastic 
activity in human osteoblast-like cell line
4
, while 
imperatorin and bergapten are effective in fetal rat 
calvariae cells
5
. High glucose levels causes a decrease 
in osteoclastogenesis and in osteoblastogenesis in vitro. 




Esculetin, a coumarin, is present in plants, such as 
Cichorium intybus, Fraxini cortex, Mori folium, 
Solanum xanthocarpum Schrad & Wendl, Artemisiae 
capillaris herba
7-10
. On analysing esculetin content of 
35 medicinal plants, it was found that Fraxini cortex 
contained the highest concentration of esculetin the 
mean of which was 3243.8 mg/kg followed by Mori 
folium and Artemisiae capillaris containing an 
average 14.7 and 13 mg/kg, respectively of esculetin
8
. 
In the uterotrophic assay, the esculetin-treated OVx 
group showed uterine weight (mg/100 g body wt.) 
less than the vehicle-treated OVx group
11
. It inhibits 
RANKL induced osteoclast differentiation. Co-culture 
of osteoclasts with primary osteoblast preserves the  
F-actin ring formation with no significant change in 
resorption pits on the hydroxyapatite plate, though the 
various transcription factors needed for osteoclast 
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. It has a bone anabolic effect on 
zebrafish larvae
13
. Esculetin, when administered at a 
dose of 384 mg/kg by oral gavage, 6 days per week 
for three months post-operatively increased the 
femoral bone mineral density
14






inhibits adipogenesis and increases antioxidant 
activity
17
. The effect of esculetin on the micro-
architecture of bones has not been studied. Micro-CT 
is the gold standard for ex vivo bone analysis
18,19
. As a 
small amount of esculetin is present in these plants, 
and when these plants are consumed as part of 
traditional medicine or as a coffee substitute or part of 
blended coffee, it reaches the systemic circulation. 
Therefore, it becomes vital to evaluate the effect of 
low doses of esculetin on various activities. 
Concentrations of esculetin 50 and 100 mg/kg cause 
an increase in uterotropic effect in immature mice
11
. 
The concentration of esculetin not affecting uterine 
proliferation would be preferred. In the present study, 
we evaluated the effect of 1.0 and 10 mg/kg esculetin 
on the microarchitecture of the bones in the 
ovariectomized rat model and studied its effect on the 
preosteoblastic cell line. 
 
Materials and Methods 
Esculetin was purchased from Sigma Aldrich. 
Commercial oestradiol valerate, the active ingredient 
of which is 17β-oestradiol (E2) (Progynova®) of 
Bayer Zydus Pharma Pvt Ltd was purchased, 
powdered, and given as a suspension intragastrically 
by oral (p.o.) gavage. MC3T3-E1 was cultured in 
complete media supplemented with penicillin and 
streptomycin solution. α-MEM and FBS were 
obtained from Gibco; -glycerophosphate, ascorbic 
acid, p-nitrophenylphosphate and 2 amino-2-methyl-
1-propranol were obtained from Sigma Aldrich.  
 
In vivo study 
The protocol was approved by the Institutional 
Animal Ethics Committee, Institute of Chemical 
Technology, Mumbai. The approval number is 
ICT/IAEC/2013/P16. Twenty female Wistar rats, 3 
months old, were acclimatized for one week. After 
acclimatization, ovariectomy (OVx) was performed 
for four groups and sham surgery was performed for 
one group
20
. The rats were allotted randomly equally 
into Sham+vehicle, OVx+vehicle, OVx+1.0 mg/kg 
esculetin, OVx+10 mg/kg esculetin, and OVx+E2 
groups. After 12 weeks of OVx, two groups of OVx 
rats were administered either esculetin 1.0 or 10 mg/kg 
daily orally, E2 group was administered as oestradiol 
0.4 mg/kg p.o. daily; other groups were administered 
vehicle (0.2% sodium CMC) p.o. On termination of 
the study, the bones (8 femurs and 8 tibias per group) 
were collected.  
 
The utility of micro-CT in osteoporotic bone has 
been established
21
. Micro computed tomography 
(Micro-CT) of excised bones was carried out using 
the Sky Scan 1076 CT scanner (Aartselaar, Belgium) 
at CDRI
22
. Three bones were scanned at a time at a 
nominal resolution (pixels) of 18 μm and the X-ray 
source was at 70kV. Reconstruction was done with 
the help of Sky Scan Nrecon software. One hundred 





bone’s volume of interest was extracted and analyzed 
by the CT analyzer software. The bone fraction i.e. 
bone volume/total volume (BV/TV), Trabecular 
Number (Tb.N), Trabecular Separation (Tb.Sp), 
Connectivity Density (Conn.Den), Trabecular 
Thickness (Tb.Th) of the femoral epiphysis and 
proximal tibial metaphysis was calculated. The 
cortical bone’s volume of interest was extracted and 
analyzed by the software. For the cortical bones Bone 
Area/Total Area (B.Ar/T.Ar), Mean Polar Moment of 
Inertia (MMI), Cross-sectional Thickness (Cs.Th) 





In vitro study 
The cell culture study was carried out at NCCS. 
Pre-osteoblastic cells MC3T3-E1 were cultured in 
complete α-MEM media supplemented with penicillin 
and streptomycin solution. The following parameters 
were determined using various concentrations of 





ALP activity and Bone nodule formation 
Cultured MC3T3-E1 cells reached confluence on 
the third day. Thereafter, 10 mM -glycerophosphate 
and 50 μg/mL of ascorbic acid were added to all wells 
except for the control without factors. Cells were 
treated with various concentrations of esculetin every 
third day from 3
rd
 day onwards. ALP activity was 
determined on the 7
th
 day and bone nodule formation 
on the 21
st
 day. ALP activity was determined using  
p-nitrophenylphosphate
25
. The bone nodules were 
stained with Alizarin Red S. They were then 
solubilised in acetic acid followed by neutralization 








Statistical analysis  
Statistical analysis was done using one-way ANOVA 




In vivo study 
 
Micro-CT of trabecular bone parameters of femur and tibia 
Esculetin treated groups showed a greater deterioration 
of BV/TV, Tb.N, Tb.Sp, Conn.Den and BMD compared 
to OVx+vehicle group in a dose-dependent manner. The 
deterioration was significantly more in the OVx+10 
mg/kg group (Tables 1 & 2). A similar effect can be 
viewed in the 3D model (Fig. 1). 
 
Micro-CT of cortical bone parameters of femur and tibia 
There was no significant change in B.Ar/T.Ar of the 
femur and tibia amongst the rats of all the groups. There 
was a substantial increase in the MMI for OVx+vehicle 
and OVx+10 mg/kg compared to Sham+vehicle in the 
case of femur and tibia. There was a significant decrease 
in Cs.Th in the femur of rats of the OVx+10 mg/kg 
 
Table 1 — Micro-CT bone parameters for femur 
Micro-CT parameters (units) Femur 
Sham+Vehicle OVx+Vehicle OVx+1.0 mg/kg OVx+10 mg/kg OVx+E2 
Trabecular 
parameters 
BV/TV (%) 26.68±1.63 17.09±1.25* 12.68±0.91* 10.83±0.85*# 15.58±1.25* 
Tb.N (per mm) 3.02±0.20 1.76±0.12* 1.49±0.09* 1.16±0.12*#@ 1.85±0.13* 
Tb.Sp(mm) 0.27±0.03 0.52±0.05* 0.8±0.02*#@ 0.76±0.05*#@ 0.56±0.06* 
Conn. Den (mm-3) 101.03±11.36  46.1±3.35* 34.67±3.9* 22.73±3.72* 47.46±3.93* 
Tb.Th (mm) 0.082±0.000 0.088±0.002* 0.085±0.002* 0.094±0.004 *#$@ 0.084±0.002* 
BMD 0.311±0.026 0.218±0.015* 0.149±0.017* 0.129±0.013*# 0.213±0.028* 
Cortical 
parameter 
B.Ar/T.Ar 0.994±0.0007 0.9947±0.0003 0.994±0.0006 0.9946±0.0003 0.993±0.0007 
MMI (mm4)  8.65±0.378 12.40±1.28* 11.02±0.63 10.57±0.53 11.32±0.4 
Cs.Th(mm) 0.567±0.014 0.554±0.009 0.527±0.015 0.498±0.007*# 0.524±0.014 
TMD 1.505±0.022 1.445±0.028 1.440±0.034 1.418±0.006 1.427±0.018 
[Sham operation was performed for one group. For all other groups, ovariectomy was done. Different groups of rats were given vehicle 
or 1mg/kg or 10mg/kg esculetin p.o. for 3 months. Values are Mean±SEM(n=4). SEM=Standard Error of Mean. Statistical analysis was 
done via ANOVA followed by Tukey’s multiple comparison test. Statistical significance * P <0.05 when various groups were compared 
to Sham+vehicle group; # P <0.05 when various groups were compared to OVx+vehicle group; @ P <0.05 when various groups were 
compared to E2+vehicle group; $ P <0.05 when various groups were compared to OVx+1.0 mg/kg] 
Table 2 — Micro-CT bone parameters for tibia 
Micro-CT parameters (units) Tibia 
Sham+Vehicle OVx+Vehicle OVx+1.0 mg/kg OVx+10 mg/kg OVx+E2 
Trabecular 
parameters 
BV/TV (%) 29.27±0.97 18.71±1.47* 14.55±1.22* 12.33±0.74*# 16.71± 0.97* 
Tb.N (per mm) 3.32±0.10 1.74±0.10* 1.57±0.14* 1.22±0.07*#@ 1.90±0.07* 
Tb.Sp (mm) 0.22±0.01 0.46±0.05* 0.54±0.05* 0.63±0.04*#@ 0.38±0.02* 
Conn. Den (mm-3) 87.32±5.57 30.92±2.29 25.16±3.03* 16.42±2.11*#@ 34.30±1.53 
Tb.Th (mm) 0.088±0.001 0.109±0.01* 0.093±0.003 0.101±0.002 0.088±0.002# 
BMD 0.404±0.025 0.315±0.035 0.217±0.027* 0.193±0.005*# 0.271±0.025* 
Cortical 
parameters 
B.Ar/T.Ar 0.968±0.002  0.970±0.002 0.964±0.003 0.967±0.002 0.970±0.002 
MMI (mm4) 3.865±0.12 5.290±0.539* 4.245±0.214 5.233±0.324* 4.889± 0.240* 
Cs.Th(mm) 0.429±0.016 0.434± 0.005 0.395±0.011 0.396± 0.006 0.420±0.014 
TMD 1.387±0.040 1.364±0.008 1.324± 0.018 1.333±0.020 1.353±0.023 
[Sham operation was performed for one group. For all other groups, ovariectomy was done. Different groups of rats were given vehicle 
or 1.0 or 10 mg/kg esculetin p.o. for 3 months. Values are Mean±SEM(n=4). SEM=Standard Error of Mean. Statistical analysis was 
done via ANOVA followed by Tukey’s multiple comparison test. Statistical significance * P < 0.05 when various groups were 
compared to Sham+vehicle group; # P <0.05 when various groups were compared to OVx+vehicle group; @ P <0.05 when various 




Fig. 1 — 3D model of tibial metaphysis. [Left to Right: Sham+Vehicle, OVx+Vehicle, OVx+1.0 mg/kg, OVx+10 mg/kg and OVx+E2. Model 
was prepared on Sky Scan 1076 CT scanner] 
 




esculetin group compared to the Sham+vehicle and the 
OVx+vehicle group. 
 
In vitro study 
 
Cell viability 
The IC50 was 65.61 μg/mL. The cell viability was 
almost similar to control for esculetin up to 10 μg/mL 
(Fig. 2). 
ALP activity 
Esculetin @0.5 and 1.0 μg/mL increased the ALP 
compared to osteogenic control, though not 
significantly. However, at 5 and 10 μg/mL it 
decreased the ALP activity in a dose-dependent way 
(Fig. 3). 
 
Alizarin Red S 
There was a significant decrease in mineral 
deposited for 5 μg/mL and 10 μg/mL dose when 
compared to osteogenic control (Fig. 4).  
 
Discussion  
Esculetin inhibits RANKL stimulated osteoclasts 
differentiation of bone marrow derived macrophages 
(BMM)
12
. It increases the femoral BMD in 
ovariectomized rats
14
, esculetin has various other 
effects i.e. anti-inflammatory, anti-adipogenesis, anti-
oxidant
15,17
. These effects pose esculetin, a dihydroxy 
coumarin, as a potential anti-osteoporotic agent. The 
effect of esculetin on microarchitecture has not been 
evaluated. Micro-CT is the gold standard for ex-vivo 
analysis of bone morphology
18,19
. We evaluated the 




Fig. 2 — Cell viability study. [MC3T3-E1 cells were cultured in 
complete media supplemented with penicillin and streptomycin 
solution. [Cell viability was determined by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay for various 
concentrations  of esculetin. . Values are expressed as 
Mean±SEM(n=4). SEM=Standard Error of Mean. Statistical analysis 
was done via ANOVA followed by Tukey’s multiple comparison test. 




Fig. 3 — ALP activity study. [MC3T3-E1 cells were cultured in 
complete media supplemented with penicillin and streptomycin solution. 
[The control group is the group to which neither osteogenic factors nor 
esculetin was added. Os. Cntrl is osteogenic control to which osteogenic 
factors (Beta Glycerophosphate and ascorbic acid) were added, however 
no esculetin was added. All other groups contain osteogenic factors 
(Beta Glycerophosphate and ascorbic acid) and 0.5 or 1 or 5 or  
10 µg/mL of esculetin. ALP activity was determined on the 7th day 
using p-nitrophenylphosphate as substrate and measured 
calorimetrically at 405 nm. Statistical analysis was done via ANOVA 
followed by Tukey’s multiple comparison test. Values show a trend 
seen in three independent experiments. They are expressed as 
Mean±SEM(n=2). SEM=Standrd Error of Mean. Statistical 
significance * P <0.05 when various groups were compared to Control 





Fig. 4 — (A) Mineralization assay; and (B) Bone nodule formation. 
[MC3T3-E1 cells were cultured in complete media supplemented with 
penicillin and streptomycin solution. The Control group is the group to 
which neither osteogenic factors nor esculetin was added. Os. Cntrl is 
osteogenic control to which osteogenic factors (Beta Glycerophosphate 
and ascorbic acid) was added, however no esculetin was added. All 
other groups contain osteogenic factors (Beta Glycerophosphate and 
ascorbic acid) and 0.5 or 1 or 5 or 10 µg/mL of esculetin. The 
mineralized nodules formed were stained on the 21st day with Alizarin 
Red S. The bone nodules stained with Alizarin Red S were solubilised 
in acetic acid, then neutralized and the optical density was read at  
405 nm. Statistical analysis was done via ANOVA followed by 
Tukey’s multiple comparison test. Values show a trend seen in three 
independent experiments. They are expressed as Mean±SEM (n=2). 
SEM, Standrd Error of Mean. Statistical significance  * P <0.05 when 
various groups were compared to Control group; # P <0.05 when 
various groups were compared to Os. Cntrl group] 
 




ovariectomized rat model. The OVx rat model, similar 
to humans, exhibits more cancellous bone loss than 
cortical bone loss
28
. OVx causes loss of estrogen’s 
protective effect; leading to increase turnover, 
increase resorption and increase susceptibility to 
fractures. This was observed via micro-CT. E2 could 
not restore the bone loss that had already taken place. 
This is in agreement with previous findings
29,30
. 
Nevertheless, E2 did not cause any further significant 
worsening in bone architecture. OVx rats treated with 
vehicle/E2/esculetin, significantly decreased bone 
fraction (BV/TV), Tb.N, Conn.Den and BMD 
compared to Sham+vehicle with a further significant 
difference in BV/TV, Tb.N, BMD for OVx+10 mg/kg 
esculetin in the long bones - femur and tibia. This 
means in the OVx+10 mg/kg esculetin group, the long 
bones were less able to bear the load and transmit the 
stress compared to the OVx+vehicle group. There was 
also a significant increase in Tb.Sp for OVx rats 
treated with vehicle/E2/esculetin compared to 
Sham+vehicle. The Tb.Sp increased significantly in 
the femur of OVx+1.0 mg/kg esculetin rats compared 
to OVx+vehicle and OVx+E2. This was significantly 
more for OVx+10 mg/kg esculetin compared to 
OVx+vehicle and OVx+E2 in femur and tibia. As the 
Tb.Sp increased this implies the bone's porosity had 
increased. The more porous the bones, the greater 
would be its fragility. The Tb.Th increased 
significantly in the OVx+10 mg/kg esculetin group 
compared to all the other groups for the femur. The 
OVx+E2 group had a decrease in Tb.Th compared to 
OVx+vehicle for the tibia. Also, the tibial Tb.Th of 
OVx+vehicle was significantly more compared to 
Sham+vehicle. The thicker the trabeculae, the more 
would be its load-bearing ability. An increase in 
Tb.Th could be a homeostatic mechanism by the body 
to retain bone functionality. As the femurs of rats 
belonging to the OVx+10 mg/kg esculetin group 
showed a significant worsening in the micro-
architecture, it could be the body’s attempt to 
conserve bone strength by increased trabecular 
thickness. With the tibia of the OVx+E2 group, 
perhaps, the deterioration was not sufficient to trigger 
the homeostatic mechanism, therefore the tibial Tb.Th 
was similar to Sham+vehicle and less compared to 
OVx+vehicle. The effects of esculetin on cortical 
bones were not much, though an increase in the 
resistance to change was seen by an increase in MMI 
in the tibia of the OVx+vehicle and OVx+10 mg/kg. 
There was a significant decrease in femoral Cs.Th. 
Thus, the cortical bone would also be more prone to 
fractures. Esculetin @ 1.0 and 10 mg/kg showed 
dose-dependent pro-osteoporotic effect in the long 
bones of OVx rats, and also augmented the effects of 




 observed an increase in femoral bone 
density, when 384 mg/kg esculetin was administered 
per day 6 days a week for 3 months post-induction of 
osteopenia. Whereas, we observed a deterioration of 
the micro-CT parameters with 1.0 and 10 mg/kg 
esculetin administered 7 days a week for 3 months. It 
could be at a higher dose the effect is mainly anti-
osteoclastic whereas at a lower dose the effect is anti-
osteoblastic. There could be a particular threshold, 
higher than it esculetin exerts an anti-osteoclastic 
effect and there could be a ceiling effect for the anti-
osteoblastic effect. The measurement method was also 
different. We used micro-CT which is the standard for 
measuring bone microarchitecture. The vehicle used 
in our study was a suspension of esculetin in 0.2% 
sodium carboxymethyl cellulose. The authors did not 
specified the vehicle used
14
. This could account for 
the difference in the absorption and thus the response. 
Also, esculetin was not administered every day of the 
week
14
. In our study, we administered esculetin daily 
for three months without a drug-free period. This may 
affect the sensitivity of esculetin at the receptor level. 
 
As the effect of esculetin on the osteoblastic cell 
line, MC3T3-E1 was not investigated, we studied its 
effect on ALP and mineralization of MC3T3-E1 cell 
line. At 5 and 10 μg/mL, esculetin reduced ALP 
activity and mineralization significantly (Figs 3 and 4). 
Concentrations higher than 10 μg/mL decreased the 
viability of MC3-T3 cells, whereas low 
concentrations of 5 and 10 μg /mL reduced the 
functions of osteoblastic cells i.e ALP activity and 
bone nodule formation. Therefore, the benefit of 
decreased resorption would be lost and would result 
in bone loss due to decreased bone formation. This 
was the effect we observed in vivo. 
 
Conclusion 
We observed esculetin showed a pro-osteoporotic 
effect in the bilateral ovariectomized rat model at 
doses of 1.0 and 10 mg/kg body wt. There was a 
worsening of the microarchitecture of the trabecular 
bone of the femur and tibia. The deterioration in bone 
quality and quantity, as seen by the deterioration of 
the micro-CT parameters, would lead to an increase in 




the susceptibility to cause fractures. This effect could 
be attributed to the osteoblast formation and function. 
Cichorium intybus contains esculetin, thus drinking 
blended coffee or coffee substitute could be one of the 
causes of osteoporosis. Also, caution needs to be 
exercised while consuming plants or 
food/beverages/herbal medicines containing esculetin. 
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